Cerebrolysin
60mg
❄️Lyophilized powder (not reconstituted)
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €44.99 |
| 11 - 20 | 15% | €42.49 |
| 21+ | 20% | €39.99 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €49.99
Cerebrolysin is supplied as a catalogued research material in 60 mg nominal catalogue presentation.
Cerebrolysin is not a single peptide, and the official branded product is a proprietary liquid porcine-brain protein hydrolysate. A generic 60 mg catalogue powder must not be assumed equivalent without matching manufacturer, composition, process and analytical documentation [1].
Chemical properties and registry information
| Property | Value |
|---|---|
| Name and synonyms | FPF-1070 |
| Material category | Nootropic / Neurotrophic |
| CAS Registry Number | 12656-61-0 |
| Structural features | A complex mixture of low-molecular-weight peptides (<10 kDa) and free amino acids derived from purified porcine brain proteins. |
| Appearance | Clear, amber-colored liquid in a glass ampoule or vial. |
| Solubility | Supplied as a ready-to-use aqueous solution for injection/infusion. Not for reconstitution. |
| Physical form | Catalogue vial; exact salt/counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
Registry values apply only to the specific molecular entity, sequence, termini and material form. Batch records take precedence over family-level literature identifiers.
Cerebrolysin is a peptidergic drug and not a single molecular entity. It consists of approximately 15% free amino acids and 85% low-molecular-weight peptides.
Research background and published evidence
Published research
The official medicinal-product specification describes a liquid formulation containing 215.2 mg of proteolytic peptide concentrate from porcine brain protein per mL; published clinical literature concerns that separately manufactured product [1,2].
Current scientific understanding
A Cochrane review of branded-product research in acute ischaemic stroke did not demonstrate a mortality benefit and reported uncertainty and a likely increase in non-fatal serious adverse events. Those findings neither support this catalogue material nor establish its equivalence [2].
The branded liquid medicine and an unverified 60 mg catalogue powder are different product presentations; naming similarity is not evidence of pharmaceutical, analytical or legal equivalence.
Technical comparison
| Aspect | This catalogue material | Comparator |
|---|---|---|
| Identity | 60 mg catalogue material with manufacturer and composition requiring verification | Authorized branded liquid Cerebrolysin medicinal product described by its official specification |
| Structural distinction | Nominal powder presentation; source, process, peptide profile and excipients are unconfirmed here | Proprietary liquid porcine-brain hydrolysate with a defined medicinal-product composition |
| Analytical implication | Requires manufacturer verification, peptide fingerprint, molecular-size distribution, amino-acid profile and batch-specific quality data | The official product specification cannot be transferred to a differently manufactured catalogue material |
Quality and testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory handling and storage
Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution's approved procedures.
Regulatory and legal status
| Research-use notice | This material is supplied exclusively for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements. |
Sources and references
- [1] EVER Pharma. Cerebrolysin official Summary of Product Characteristics.
- [2] Cochrane Review. Cerebrolysin for acute ischaemic stroke (2023 update).
Frequently Asked Questions
Do the CAS number and PubChem CID apply to every batch form?
Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.
What does an analytical purity result mean?
It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.
How should the material be stored and handled?
Follow the exact label, batch CoA and SDS together with the institution's risk assessment. Use only storage and stability information linked to the exact material form and batch.